"The
Report Spinocerebellar Ataxia (SCA) - Pipeline Review, H1 2016
provides information on pricing, market analysis, shares, forecast,
and company profiles for key industry participants. -
MarketResearchReports.biz"
Global Markets Directs,
Spinocerebellar
Ataxia (SCA) -
Pipeline Review, H1 2016, provides an overview of the Spinocerebellar
Ataxia (SCA) pipeline landscape.
The report provides
comprehensive information on the therapeutics under development for
Spinocerebellar Ataxia (SCA), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The report also covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
Additionally, the report provides an overview of key players involved
in therapeutic development for Spinocerebellar Ataxia (SCA) and
features dormant and discontinued projects.
Global Markets Directs report
features investigational drugs from across globe covering over 20
therapy areas and nearly 3,000 indications. The report is built using
data and information sourced from Global Markets Directs proprietary
databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press
releases from company/university sites and industry-specific third
party sources. Drug profiles featured in the report undergoes
periodic review following a stringent set of processes to ensure that
all the profiles are updated with the latest set of information.
Additionally, various dynamic tracking processes ensure that the most
recent developments are captured on a real time basis.
The report helps in identifying
and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/742824
Scope
- The report provides a
snapshot of the global therapeutic landscape of Spinocerebellar
Ataxia (SCA)
- The report reviews pipeline
therapeutics for Spinocerebellar Ataxia (SCA) by companies and
universities/research institutes based on information derived from
company and industry-specific sources
- The report covers pipeline
products based on various stages of development ranging from
pre-registration till discovery and undisclosed stages
- The report features
descriptive drug profiles for the pipeline products which includes,
product description, descriptive MoA, R&D brief, licensing and
collaboration details & other developmental activities
- The report reviews key
players involved Spinocerebellar Ataxia (SCA) therapeutics and
enlists all their major and minor projects
- The report assesses
Spinocerebellar Ataxia (SCA) therapeutics based on drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type
- The report summarizes all the
dormant and discontinued pipeline projects
- The report reviews latest
news related to pipeline therapeutics for Spinocerebellar Ataxia
(SCA)
Reasons to buy
- Gain strategically
significant competitor information, analysis, and insights to
formulate effective R&D strategies
- Identify emerging players
with potentially strong product portfolio and create effective
counter-strategies to gain competitive advantage
- Identify and understand
important and diverse types of therapeutics under development for
Spinocerebellar Ataxia (SCA)
- Identify potential new
clients or partners in the target demographic
- Develop strategic initiatives
by understanding the focus areas of leading companies
- Plan mergers and acquisitions
effectively by identifying key players and its most promising
pipeline therapeutics
- Devise corrective measures
for pipeline projects by understanding Spinocerebellar Ataxia (SCA)
pipeline depth and focus of Indication therapeutics
- Develop and design
in-licensing and out-licensing strategies by identifying prospective
partners with the most attractive projects to enhance and expand
business potential and scope
- Modify the therapeutic
portfolio by identifying discontinued projects and understanding the
factors that drove them from pipeline
Table
of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report
Coverage 5
Spinocerebellar Ataxia (SCA)
Overview 6
Therapeutics Development 7
Pipeline Products for
Spinocerebellar Ataxia (SCA) - Overview 7
Pipeline Products for
Spinocerebellar Ataxia (SCA) - Comparative Analysis 8
Spinocerebellar Ataxia (SCA) -
Therapeutics under Development by Companies 9
Spinocerebellar Ataxia (SCA) -
Therapeutics under Investigation by Universities/Institutes 10
Spinocerebellar Ataxia (SCA) -
Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Spinocerebellar Ataxia (SCA) -
Products under Development by Companies 14
Spinocerebellar Ataxia (SCA) -
Products under Investigation by Universities/Institutes 15
Spinocerebellar Ataxia (SCA) -
Companies Involved in Therapeutics Development 16
Baxalta Incorporated 16
Bioblast Pharma Ltd. 17
Kissei Pharmaceutical Co., Ltd.
18
Vybion, Inc. 19
Spinocerebellar Ataxia (SCA) -
Therapeutics Assessment 20
Assessment by Monotherapy
Products 20
Assessment by Target 21
Assessment by Mechanism of
Action 23
Assessment by Route of
Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
Antisense RNAi Oligonucleotide
to Inhibit Ataxin-7 for Spinocerebellar Ataxia Type 7 - Drug Profile
29
Product Description 29
Mechanism of Action 29
R&D Progress 29
epoetin alfa - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
immune globulin (human) - Drug
Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment